{"id":"NCT00610675","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)","officialTitle":"Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12-07","primaryCompletion":"2009-08-17","completion":"2009-08-17","firstPosted":"2008-02-08","resultsPosted":"2014-07-30","lastUpdate":"2018-10-03"},"enrollment":346,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Insomnia"],"interventions":[{"type":"DRUG","name":"Org 50081","otherNames":[]}],"arms":[{"label":"Esmirtazapine","type":"EXPERIMENTAL"}],"summary":"This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706) (NCT00482612) or 176002 (P05707) (NCT00506389). Participants who have completed Protocol P05706 or P05707, and are willing to continue treatment with Esmirtazapine, can participate in Protocol 176004 (P05708) after signing informed consent.","primaryOutcome":{"measure":"Number of Participants With an Adverse Event","timeFrame":"Up to 57 weeks","effectByArm":[{"arm":"Esmirtazapine","deltaMin":235,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":342},"commonTop":["Weight increased","Somnolence","Nasopharyngitis","Upper respiratory tract infection"]}}